1Lackowska B, Niezabitowski A, Rys J,et al. S-phase fraction and menopausal status as the most important prognostic factors of disease-free survival for node negative patients with breast cancer. A prospective study. Pol J Pathol,2003,54(2) :101-110.
2Elkhuizen PH,Voogd AC,van den Broek LC,et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncngene expression. Int J Radiat Oncol Biol Phys, 199
3Janicke F,Prechtl A,Thomssen C,et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst , 2001,
4Harbeck N,Meisner C,Prechtl A, et al. Level-1 evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N-0 therapy trial. Breast Cancer Res Treat, 2001, 69(3 )
5Elledge RM,Green S,Pugh R,et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology
6Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res,2001,7(9) :2703-2711.
7Pienkowski T,Olszewski W,Kraszewakas E,et al. Predictive value of HER-2 receptor, P53, bcl-2 and bax proteins, MB-1 antibody,estrogene and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen. Eur J Cancer, 2002, 38 (Sup
8Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg,2000,87(4):405-409.
9Esteva FJ, Hortobagyi GN, Sahin AA, et al. Expression of erbB/HER receptors, haregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res, 2001, 7(3): 171-177.
10Bull SB, Ozcelik H, Pinnaduwage D, et al. The combination of p53mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol, 2004, 22(1) :86-96.
